Interview with Merab Kokaia concerning CombiGene’s long-term study

The long-term study, part of CombiGene’s epilepsy project, is a decisive preclinical proof-of-concept-study, the results of which will have a great bearing on the continued development of CombiGene’s candidate drug, CG01.
Heading the study at Skåne University Hospital is Professor Merab Kokaia, one of CombiGene’s scientific founders.
Merab Kokaia comments on the study:

CombiGene Intervju Merab_English from CombiGene on Vimeo.